Sakar Healthcare Limited (NSE:SAKAR)

Market Cap	11.75B +131.4%
Revenue (ttm)	2.31B +35.2%
Net Income	252.21M +69.7%
EPS	11.37 +66.0%
Shares Out	22.25M
PE Ratio	46.45
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,671
Average Volume	191,465
Open	515.45
Previous Close	527.95
Day's Range	505.35 - 534.50
52-Week Range	210.10 - 569.95
Beta	0.10
RSI	64.18
Earnings Date	May 20, 2026

About Sakar Healthcare

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaestheti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 342
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SAKAR

Financial Performance

In fiscal year 2025, Sakar Healthcare's revenue was 1.78 billion, an increase of 15.53% compared to the previous year's 1.54 billion. Earnings were 175.02 million, an increase of 49.96%.